Acura Pharmaceuticals(OTC) ACUR

Acura Pharmaceuticals, Inc. is a drug delivery innovator focused on developing technologies that enhance medication safety. The company offers a range of products, including prescription and over-the-counter medications, aimed at addressing pain management and cold relief.

Products and Services

• Oxaydo tablets for managing moderate-to-severe pain
• Nexafed line for cold and allergy relief
• Six additional opioid products in development

Growth Outlook

• Strategic partnerships with Egalet for global commercialization
• Advancing LTX-03 using proprietary LIMITx technology
• Focus on expanding product portfolio to meet market needs

Financial Highlights

• Recent quarterly revenue of $36,000, showing potential for growth
• Trailing twelve months (TTM) gross profit margin at 94.24%
• Current ratio of 0.72 indicates liquidity management challenges

Acura Pharmaceuticals operates in the healthcare sector, specifically within the drug manufacturing industry. The company is headquartered in Palatine, Illinois, and has been in operation since 1935. Acura's commitment to innovation is evident in its product offerings, which include Oxaydo, a prescription medication designed to manage pain while minimizing the risk of misuse. The Nexafed line serves as an effective solution for cold and allergy symptoms, further diversifying the company's portfolio. The growth outlook for Acura Pharmaceuticals is bolstered by strategic collaborations, particularly with Egalet US, Inc. and Egalet Ltd., which facilitate the global production and commercialization of its products. Additionally, the development of LTX-03, an immediate-release tablet utilizing LIMITx technology, showcases the company's dedication to advancing medication safety. Financially, Acura has shown a recent quarterly revenue of $36,000, indicating potential for future growth. The trailing twelve months gross profit margin stands at an impressive 94.24%, reflecting the company's ability to maintain profitability despite challenges. However, the current ratio of 0.72 suggests that liquidity management may require attention. Overall, Acura Pharmaceuticals presents an intriguing opportunity for investors interested in the healthcare sector, particularly in innovative drug delivery solutions. The company's focus on safety and efficacy in medication aligns with growing market demands, positioning it for potential growth in the coming years.